Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis
- PMID: 27740723
- PMCID: PMC5396299
- DOI: 10.1002/ppul.23570
Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis
Abstract
Background: Respiratory syncytial virus (RSV) is a major public health burden worldwide. We aimed to review the current literature on the incidence and mortality of severe RSV in children globally.
Methods: Systematic literature review and meta-analysis of published data from 2000 onwards, reporting on burden of acute respiratory infection (ARI) due to RSV in children. Main outcomes were hospitalization for severe RSV-ARI and death.
Results: Five thousand two hundred and seventy-four references were identified. Fifty-five studies were included from 32 countries. The global RSV-ARI hospitalization estimates, reported per 1,000 children per year (95% Credible Interval (CrI), were 4.37 (2.98, 6.42) among children <5 years, 19.19 (15.04, 24.48) among children <1 year, 20.01 (9.65, 41.31) among children <6 months and 63.85 (37.52, 109.70) among premature children <1 year. The RSV-ARI global case-fatality estimates, reported per 1,000 children, (95% Crl) were 6.21 (2.64, 13.73) among children <5 years, 6.60 (1.85, 16.93) for children <1 year, and 1.04 (0.17, 12.06) among preterm children <1 year.
Conclusions: A substantial proportion of RSV-associated morbidity occurs in the first year of life, especially in children born prematurely. These data affirm the importance of RSV disease in the causation of hospitalization and as a significant contributor to pediatric mortality and further demonstrate gestational age as a critical determinant of disease severity. An important limitation of case-fatality ratios is the absence of individual patient characteristics of non-surviving patients. Moreover, case-fatality ratios cannot be translated to population-based mortality. Pediatr Pulmonol. 2017;52:556-569. © 2016 The Authors. Pediatric Pulmonology. Published by Wiley Periodicals, Inc.
Keywords: burden; epidemiology; infant; morbidity; preterm.
© 2016 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.
Figures
Similar articles
-
Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.Lancet. 2024 Mar 30;403(10433):1241-1253. doi: 10.1016/S0140-6736(24)00138-7. Epub 2024 Feb 14. Lancet. 2024. PMID: 38367641
-
Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis.J Glob Health. 2015 Dec;5(2):020416. doi: 10.7189/jogh.05.020416. J Glob Health. 2015. PMID: 26682048 Free PMC article. Review.
-
Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of northern India.J Glob Health. 2015 Dec;5(2):010419. doi: 10.7189/jogh.05.020419. J Glob Health. 2015. PMID: 26649172 Free PMC article.
-
Respiratory syncytial virus infection in Guatemala, 2007-2012.J Infect Dis. 2013 Dec 15;208 Suppl 3:S197-206. doi: 10.1093/infdis/jit517. J Infect Dis. 2013. PMID: 24265479
-
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.Lancet. 2017 Sep 2;390(10098):946-958. doi: 10.1016/S0140-6736(17)30938-8. Epub 2017 Jul 7. Lancet. 2017. PMID: 28689664 Free PMC article. Review.
Cited by
-
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Cochrane Database Syst Rev. 2024. PMID: 38695784 Review.
-
Impact of including productivity costs in economic analyses of vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting.Cost Eff Resour Alloc. 2024 Apr 30;22(1):34. doi: 10.1186/s12962-024-00533-4. Cost Eff Resour Alloc. 2024. PMID: 38689331 Free PMC article.
-
Impact of COVID-19 Nonpharmaceutical Interventions on Respiratory Syncytial Virus Infections in Hospitalized Children.Influenza Other Respir Viruses. 2024 Apr;18(4):e13291. doi: 10.1111/irv.13291. Influenza Other Respir Viruses. 2024. PMID: 38653953 Free PMC article.
-
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.BMC Infect Dis. 2024 Apr 19;24(1):418. doi: 10.1186/s12879-024-09300-5. BMC Infect Dis. 2024. PMID: 38641577 Free PMC article.
-
Pre-COVID-19-pandemic RSV epidemiology and clinical burden in pediatric primary care in Italy: a comparative analysis across two regions for the 2019/2020 season.BMC Infect Dis. 2024 Apr 11;24(1):388. doi: 10.1186/s12879-024-09229-9. BMC Infect Dis. 2024. PMID: 38605310 Free PMC article.
References
-
- Bryce J, Boschi‐Pinto C, Shibuya K, Black RE. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005; 365:1147–1152. - PubMed
-
- Iwane MK, Farnon EC, Gerber SI. Importance of global surveillance for respiratory syncytial virus. J Infect Dis 2013; 208:S165–S166. - PubMed
-
- Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 2013; 372:39–57. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical